Basics |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
|
IPO Date: |
September 1, 2014 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$1.21B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.23 | 2.72%
|
Avg Daily Range (30 D): |
$0.21 | 2.47%
|
Avg Daily Range (90 D): |
$0.15 | 1.87%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.73M |
Avg Daily Volume (30 D): |
1.51M |
Avg Daily Volume (90 D): |
1.25M |
Trade Size |
Avg Trade Size (Sh.): |
171 |
Avg Trade Size (Sh.) (30 D): |
119 |
Avg Trade Size (Sh.) (90 D): |
108 |
Institutional Trades |
Total Inst.Trades: |
2,326 |
Avg Inst. Trade: |
$1.22M |
Avg Inst. Trade (30 D): |
$1.53M |
Avg Inst. Trade (90 D): |
$1.34M |
Avg Inst. Trade Volume: |
.11M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.28M |
Avg Closing Trade (30 D): |
$1.38M |
Avg Closing Trade (90 D): |
$1.1M |
Avg Closing Volume: |
128.13K |
|
|
Financials |
|
TTM |
Q1 2025 |
Q3 2024 |
Basic EPS
|
|
$.17
|
$.1
|
Diluted EPS
|
|
$.16
|
$.1
|
Revenue
|
$
|
$ 62.47M
|
$ 67.77M
|
Gross Profit
|
$
|
$ 53.89M
|
$ 61.74M
|
Net Income / Loss
|
$
|
$ 23.34M
|
$ 14.35M
|
Operating Income / Loss
|
$
|
$ 21.85M
|
$ 11.75M
|
Cost of Revenue
|
$
|
$ 8.57M
|
$ 6.04M
|
Net Cash Flow
|
$
|
$ -17.01M
|
$ 3.74M
|
PE Ratio
|
|
|
|
Splits |
Oct 23, 2013:
1:50
|
|
|
|